Provided by Tiger Trade Technology Pte. Ltd.

Trump Concept

3,236.42
+42.101.32%
Number of Gainers:18
Number of Losers:11
Number of Flat:2
PE:- -
High:3,260.68
Open:3,195.34
Low:3,195.34
Close:3,194.32
Volume:404.56M
Turnover:53.61B
Market Cap:6.14T
Float Cap:5.42T

Loading ...

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Tesla Consensus Sees Q3 2026 Total Deliveries at 461,974 Vehicles

Reuters
·
Sep 30

Ford is Worried About a Labor Shortage and What That Means for Manufacturing

Dow Jones
·
Sep 30

Anthropic's Potential $2 Trillion-Plus IPO Supports Robust AI Infrastructure Spending, Wedbush Says

MT Newswires Live
·
Sep 30

Fortem Technologies Closes $50 Mln Series B Financing Led by Lockheed Martin

Reuters
·
Sep 30

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Easa: We Would not Speculate on the Reported Actions or Motivations of the Individuals Involved, or Draw Conclusions About Pilot Fitness or Other Possible Contributing Factors

THOMSON REUTERS
·
Sep 30

European Aviation Safety Agency: Collecting Additional Information from Flydubai and the UAE General Civil Aviation Authority on Today's Incident

THOMSON REUTERS
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

General Motors launches OnStar Fleet Intelligence platform

TIPRANKS
·
Sep 30

Morgan Stanley Currently Down Seven Consecutive Days, on Track for Longest Losing Streak Since January 2024

Dow Jones
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Ford F-150 Supplier Disruption Impacting 3Q Wholesale Numbers but Issue Resolved, CEO Says

THOMSON REUTERS
·
Sep 30

US Stocks-Wall St Climbs as Cooling Inflation Tempers Fed Rate-Hike Concerns

Reuters
·
Sep 30

Shanghai United Media Group's Open Class Explores How Village Basketball League Became a Media-Driven Industry IP

Deep News
·
Sep 30